UCB (MEX:UCBN) ROE % Adjusted to Book Value: 14.74% (As of Dec. 2025)


MEX:UCBN UCB SA MEX:UCBN
85 GF Score
Price MXN1,692.27
GF Value MXN1,417.06
! 2 Warning Signs
View Full Analysis

What is UCB ROE % Adjusted to Book Value?

UCB MEX:UCBN 85 ROE % Adjusted to Book Value is 14.74% as of Dec. 2025. GuruFocus rates MEX:UCBN with a GF Score™ of 85/100 and a GF Value™ of MXN1,417.06. The stock has 2 warning signs investors should review.

UCB's ROE % for the quarter that ended in Dec. 2025 was 20.78%. UCB's PB Ratio for the quarter that ended in Dec. 2025 was 1.41. UCB's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 14.74%.

UCB ROE % Adjusted to Book Value Related Terms

UCB ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for UCB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCB ROE % Adjusted to Book Value Chart

UCB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.94 2.64 1.86 8.22 10.40

UCB Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 2.63 12.87 6.28 14.74

MEX:UCBN vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, UCB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UCB ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UCB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where UCB's ROE % Adjusted to Book Value falls into.


MEX:UCBN
85GF Score
UCB SA MEX:UCBN
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UCB ROE % Adjusted to Book Value Calculation

UCB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=14.66% / 1.41
=10.40%

UCB's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=20.78% / 1.41
=14.74%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 14.74% mean?
UCB (MEX:UCBN) has a ROE % Adjusted to Book Value of 14.74% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on UCB and its competitors.
Is UCB's ROE % Adjusted to Book Value too high?
UCB's current ROE % Adjusted to Book Value is 14.74%. Overall, UCB has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does UCB's ROE % Adjusted to Book Value compare to VRTX and REGN?
UCB's ROE % Adjusted to Book Value of 14.74% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on UCB and its competitors. UCB's current ROE % Adjusted to Book Value is 14.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
UCB (MEX:UCBN) has a current ROE % Adjusted to Book Value of 14.74%. The stock's GF Value™ is MXN1,417.06, compared to a current price of MXN1,692.27 — trading 19.4% above its estimated fair value. The current ROE % Adjusted to Book Value is 14.74%. UCB's overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For UCB (MEX:UCBN), the current ROE % Adjusted to Book Value is 14.74% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UCB (MEX:UCBN) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be overvalued. The current stock price of MXN1,692.27 is trading 19.4% above its estimated GF Value™ of MXN1,417.06.

Key valuation signals for MEX:UCBN:

  • ROE % Adjusted to Book Value: 14.74%
  • GF Value™: MXN1,417.06 vs. price of MXN1,692.27 (19.4% above fair value)
  • GF Score™: 85/100 with 2 warning signs

No single metric tells the full story. See the MEX:UCBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
85GF Score

Get the complete analysis for MEX:UCBN

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,692.27
Price
MXN1,417.06
GF Value